LAURUSLABS Q4 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,440 Cr
verified against source
Revenue YoY
-17%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laurus Labs reported Q4 FY2024 revenue of INR 1,440 crore (+4% YoY, +21% QoQ), with FY2024 revenue at INR 5,041 crore (-17% YoY due to no COVID supplies). EBITDA margin came in at 18% for Q4 and 16% for FY2024, reflecting higher OpEx on growth projects and R&D spend (4.8% of sales). ROCE declined sharply to 6.4% from 21.3% due to lower operating results and heavy capital deployment. Net debt stands at INR 2,368 crore with debt/EBITDA at 3x. The quarter saw strong Onco API performance (INR 147 crore, highest ever), ARV stabilization, and new US product launches (2 in Q4, 2 under preparation). CDMO business remained flat at INR 922 crore for FY2024. Management targets CDMO contribution to grow to one-third of revenue, with meaningful contributions from Animal Health in FY2025 and peak revenues in FY2027. The key risk is the elevated debt burden and slow ramp-up of new CDMO capacities, which may pressure margins until utilization improves.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects CDMO (including synthesis and bio) to grow from ~20% to approximately one-third of total revenue in the next couple of years, driven by Animal Health commercialization and new client additions.
- Animal Health facility (fully contracted with big pharma partner) will start commercial supplies in FY2025, with peak revenues expected in FY2027. Commercial validation for ~4 products will be completed this financial year.
- GLP/GMP plant construction for viral vectors and gene therapy products at IIT Kanpur is underway, targeting Phase 1 operations by end of Q3 FY2025. CapEx and OpEx could be ~INR 300 crore over next 2-3 years, contingent on clinical trial progress.
- Biologics division is expected to achieve peak revenues during FY2025, with downstream R2 capacity increased by 20% and enzyme engineering expanding for small molecule, clinical and commercial API projects.
Risks flagged
- Net debt of INR 2,368 crore with debt/EBITDA at 3x (vs historical range). Management aims to reduce this to below 2x as EBITDA improves, but the high debt burden constrains financial flexibility and increases vulnerability to any revenue shortfalls.
- CDMO revenue has remained essentially flat at ~INR 900 crore over FY2022-FY2024 despite significant CapEx deployment. Management acknowledged this 'transitionary period' but gave no specific timeline for meaningful acceleration beyond Animal Health ramp-up.
- Other API segment (cardiovascular, diabetes, asthma) declined 22% in FY2024 due to challenging price environment, with management indicating pricing headwinds may continue into FY2025. This segment represents ~25% of API sales but affects overall margins.
- While the company added 2 new CDMO clients and is receiving more RFPs, management explicitly stated 'nothing meaningful will come in the 12 months from the new clients' and that onboarding takes time. Analysts questioned the gap between pipeline activity and revenue conversion.
Key quotes
- FY 2020 to FY 2024 revenues were same. It is true. But the typical development timeline is seven to eight years. If it is very short range, five to six years. We have projects in different phases of their life cycle.
- These initiatives are putting very, very interesting for long term, but short term, these are very painful investments because we are investing in CapEx, OpEx and all these are going through the balance sheet. But one has to realize that your company is putting money in the right places for long-term and sustainable growth.
- The shift in big pharma to diversify their vendor base has started. It is also very clear we got more RFPs in the last 12 months for late-phase projects when compared to previous years. That is an indication that there is a diversification effort from big pharma, and it is clearly visible.
Research modules